Infectious Diseases (ID) Fellowship Training is a 2-3 year program depending on the track the fellow chooses. The fellowship tracks are designed to meet all ACGME training requirements and 12 months of clinical experience and 24 months of continuity clinic experience for ABIM subspecialty board eligibility...


Suppose you lived in the mid-1800s in Cleveland, population 17,000. You likely wouldn't have ventured beyond the surrounding countryside, perhaps 10 to 20 miles at most, during your lifetime. Fast-forward to Cleveland today, population about 400,000. Air travel makes it possible to...

International Doctors

The international competition for postgraduate positions at University Hospitals Case Medical Center each year is a testament to the stature of our academic medical center among high-potential young physicians. This is especially true of more than 200 prestigious UH Case Medical Centerfellowships, which are globally recognized for preparing future leaders in medicine.

frame image
frame image

Welcome from the Division Chief

Welcome to the website for the Division of Infectious Diseases & HIV Medicine at Case Western Reserve University. We are incredibly proud of our tradition and accomplishments in contributing to the advancement of treatment of infectious diseases locally, nationally and worldwide.

Our core mission is to heal, to teach and to discover. Facing the challenges of emerging and re-emerging infectious diseases at home and across the globe; we pride ourselves on delivering the highest quality of care for our patients, providing exceptional fellowship training to the next generation of Infectious Diseases physicians and continuing to make scientific breakthroughs through our world renowned research.

CWRU wins $12.7 million for AIDS research, clinical trials

AIDS researchers from Case Western Reserve University and University Hospitals Case Medical Center have received a seven-year funding award from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH).

This award includes $12.7 million for core research funding and the potential of an additional $9 million to support clinical trials of promising treatments. This award marks the fifth time the Case Western Reserve University (CWRU)/University Hospitals (UH) AIDS Clinical Trials Unit has received NIAID funding since it began operating in 1987.

"We are very proud to have received this competitive award," said co-principal investigator Michael Lederman, the Scott R. Inkley Professor of Medicine and associate director of the Center for AIDS Research at Case Western Reserve School of Medicine and infectious disease specialist at UH Case Medical Center. "It shows a level of confidence in our unit that encourages and inspires us." Read more...

CWRU researchers heading teams chosen by amfAR to pursue research for eradicating HIV and AIDS

By Angela Townsend, The Plain Dealer CLEVELAND, Ohio -- Two Case Western Reserve University scientists are each heading up research teams chosen by New York-based amfAR, The Foundation for AIDS Research, to receive funding for projects aimed at eliminating AIDS. The group this week announced more than $900,000 in grants that will be divided among five teams. The latest round of awards is part of amfAR's Research Consortium on HIV Eradication (ARCHE) program launched in 2010. Read the article.

STERIS Grant 2013 Awardees

STERIS GrantThe Division of Infectious Diseases & HIV Medicine at Case Western Reserve University and University Hospitals Case Medical Center, with funds from STERIS Corporation, are providing seed money to faculty to foster research in emerging and healthcare-associated infections. Investigators in the basic science and clinical departments in the School of Medicine and Hospital System as well as in other departments throughout the University were awarded. Awardees are as follows:

  • Christine McDonald, PhD - Department of Pathobiology - Enhancement of cutaneous antimicrobial defenses to target MRSA infection
  • Pushpa Pandiyan, MSc, PhD - School of Dental Medicine - A mechanism of immunomodulation during Oropharyngeal candidiasis
  • Daniel Popkin, MD, PhD; Nicole Steinmetz, PhD (Co-PI) - Dermatology | Pathology | Microbiology & Molecular Biology (Popkin); Biomedical Engineering | Radiology | Materials Science and Engineering (Steinmetz) - Purging persistent viral infection with nanoparticle "seek and protect" therapy of pAPC
  • Roxana Rojas, PhD - Infectious Diseases & HIV Medicine - Host oxidoreductases as targets of TB drugs
  • Marion Skalweit, MD, PhD - Infectious Diseases & HIV Medicine - Bulgecin A for Resistant Gram-negatives

ClinicalRM Awarded NIH Contract to Support the STI CTG Program

September 10, 2013, Hinckley, OH – Clinical Research Management, Inc. (ClinicalRM) – a full-service Contract Research Organization (CRO) providing services for basic and applied research, clinical trials, and regulatory support – announced today it was awarded a contract by the Department of Health and Human Services, National Institutes of Health, Division of Microbiology and Infectious Diseases (DMID) of the National Institute of Allergy and Infectious Diseases (NIAID). Read the article.

Robert Salata


  • The ID Alliance, led by Dr. Amanda Healan and Dr. Robert Salata, has successfully earned funding from the United Black Fund of Greater Cleveland ($5,000) and The Cleveland Foundation ($25,000) to sustain its Peer Educator program. The program teaches high school students about sexually transmitted infections (STIs) and effective prevention strategies. Peer Educators are empowered to facilitate educational workshops for other youth groups. Funding will be utilized for Peer Educator stipends and to support open Peer Educator training sessions twice monthly at J. Glen Smith Health Center. The training sessions are part of Teen Night Tuesdays at the health center, which the ID Alliance co-sponsors. For more information, visit www.IDAlliance.org or contact IDAlliance@case.edu.
  • Case Western Reserve University recently became a site institution for the the Sexually Transmitted Infections Clinical Trials Group (STI CTG) with Robert A. Salata, M.D. as the PI. There were only 3 awards nationally for funding over 7 years. The STI-CTG is a collaboration of institutions that work together to identify, support, and administer clinical trials that will contribute to the reproductive health of people and specifically lead to prevention and control of sexually transmitted infections (STIs). This award is through the National Institutes of Health and the National Institute for Allergy and Infectious Diseases administered through the Division of Microbiology and Infectious Diseases (DMID).
  • Drs. Jump (Robin Jump, MD, PhD), Olds and Higgins, together with their colleagues Dr. Ken Schaemder from the VA in Durham, NC and Dr. Chris Crnich from the VA in Madison, WI, were awarded $247,000 from the VA Geriatric Research Education and Clinical Center (GRECC). Their proposal, "A Multi-Site Educational Intervention to Improve the Treatment of Infections Among Older Veterans," will implement two educational tracks, one for prescribers and one for nursing staff, across several VA facilities. Their long-term goal is to improve antimicrobial utilization for older adults.
  • Robert A. Salata, MD, Chief of the Division of Infectious Diseases and HIV Medicine, and Medical Director, Infection Control and Prevention at UH Case Medical Center, is principal investigator of a study to evaluate the safety, tolerability and appropriate dosing for aerosol and intravenous versions of an antibiotic called colistin. This drug was introduced in the 1960s, and was never subjected to the testing that modern regulatory review requires. Therefore, the best and safest ways to use it against most infections are largely unknown. The National Institutes of Health funded the study through a one-of-a-kind contract with Case Western Reserve University School of Medicine specifically awarded for phase 1 clinical trials in infectious disease.
  • Dr. Usha Stiefel's independent proposal entitled "Role of Microbial Eradication in Preventing Recurrent MRSA Infection" was selected for a 2012 ASPIRE Award. The ASPIRE Awards in Antibacterial Research are competitive, externally reviewed grant awards sponsored by Pfizer, Inc. The project will evaluate the hypothesis that antimicrobials displaying superior rates of microbial eradication and superior rates of intestinal pathogen eradication will be associated with decreased rates of recurrent infection with methicillin-resistant Staphylococcus aureus (MRSA) in veteran patients.